Lung Cancer Testing

NeoGenomics is answering the challenges of cancer testing

Introducing NeoTYPE® DNA & RNA – Lung: Our new, targeted, tissue-based assay

RNA NGS optimizes gene fusion detection: This profile features RNA-based fusion detection, which has advantages over DNA-based fusion detection.

  • RNA detection sensitivity of nearly 100%1 exceeds that of DNA2,3
  • RNA detects expressed rather than predicted fusion sequences, providing better evidence of driver activity4
  • RNA avoids technically complex gene intron regions4
  • Known and novel fusions of targeted genes are reported

Reflex to liquid biopsy is available: If tissue testing doesn’t yield full results, we can proceed with mobile phlebotomy (if requested) and high-sensitivity ctDNA testing with InVisionFirst®-Lung Liquid Biopsy.

The Lilly Lung Cancer Sponsored Testing Program: Provides access to CGP testing with NeoTYPE® DNA & RNA – Lung (and reflex to liquid biopsy if needed) at no cost for eligible patients*. This is only available through NeoGenomics.

male staring out of window

Why Consider NeoTYPE® DNA & RNA – Lung?

  • Maximizes molecular information: both DNA- and RNA-based NGS are included in a single test.
  • Minimizes QNS rates: up to 38% of NSCLC patients have insufficient tissue.5,6,7
  • Simple: the targeted panel provides just the right amount of information to manage aNSCLC patients.
  • Timely: turnaround time of 14 days allows for prompt follow-up on therapeutic and clinical trial opportunities.

QNS = quantity not sufficient.

When tumor tissue is unavailable, consider liquid biopsy testing for rapid biomarker results.

Learn more about InVisionFirst®-Lung Liquid Biopsy

Lilly Lung Sponsored Testing Program is now available

Sponsored testing with NeoTYPE® DNA & RNA – Lung provides access to CGP testing at no cost for eligible patients, exclusively through NeoGenomics.

Comprehensive yet targeted biomarker testing balances the patient’s need for precision medicine with demands on small specimens.

With the tremendous growth in FDA-approved targeted therapies and immunotherapies for lung cancer, proper test selection for precision medicine-based patient management is critical. NeoGenomics understands that tissue is precious, and our dedicated team of expert pathologists prioritize every sample to get you the results you need. If tissue is not available, NeoGenomics offers liquid biopsy testing to provide the genomic results needed to initiate or adjust treatment.

Whether single-gene assays, comprehensive genomic profiling (CGP) or liquid biopsy, NeoGenomics offers a broad portfolio of lung cancer tests to serve all patients along the cancer journey.

NeoGenomics is your single destination for all stages of lung cancer

Immuno-Oncology

Immuno-Oncology (I-O), also known as cancer immunotherapy, is a type of cancer treatment that boosts one’s own immune system to fight cancer. Often, if cancer cells have high levels of PD-L1, a predictive biomarker detectable by immunohistochemistry, patients may benefit from immunotherapy.

NeoGenomics was the first oncology diagnostic laboratory to run PD-L1 testing with the launch of pembrolizumab immunotherapy and remains a key provider of immuno-oncology testing, running over 70,000 PD-L1 tests annually.

Please contact us for our Checkpoint Inhibitor Guide to learn more about the suite of companion and complementary PD-L1 testing offered.

Molecular Diagnostics

Tumor profiling has become fundamental to inform cancer diagnosis and prognosis but also to drive therapeutic decisions in clinical practice. Tailored to fit the many clinical needs of patients and oncology providers, NeoGenomics offers a variety of comprehensive and targeted approaches to drive precision medicine decisions in patients with lung cancer. Our multi-modal panels provide clear results on tumor-specific alterations, immune-oncology expression and access to open clinical trials. Please learn more about our tumor profiles.

NeoTYPE® DNA & RNA – Lung is our new, targeted, tissue-based assay that maximizes molecular information and minimizes QNS (Quantity Not Sufficient). This simplified NeoTYPE® Cancer Profile tests for 50 genes + 3 biomarkers in one test to give you the predictive and prognostic answers you need, and a 14-day turnaround time.

NeoTYPE® Lung Tumor Profile is a targeted molecular profile designed to detect genomic alterations in clinically significant driver genes based on multi-method detection techniques centered primarily on next-generation sequencing, but also including selected immunohistochemical and FISH assays.

The Lung NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions of the genes ALK, NRG1, NTRK1, NTRK2, NTRK3, RET and ROS1 with known and novel fusion partners.

NeoTYPE® Discovery Profile analyzes 336 biomarkers through a combination of next-generation sequencing (NGS), FISH and immunohistochemistry.

Single-Gene Assays

Biomarker profiling is crucial for patients with lung cancer and key to initiate precision medicine decisions.

Comprehensive or broad panel testing may not be an option for all patients. Please visit our test menu to learn more about our single-biomarker assays such as EGFR, ROS1, ALK, NTRK, BRAF, PD-L1 and many more.

Liquid Biopsy Testing

Liquid biopsy in cancer testing is a unique approach to genomic profiling. Although tissue-based assays are the gold standard to tumor profiling, quality and availability of tumor tissue often times poses a challenge to implement precision medicine. Liquid biopsies are easily accessible through a simple blood draw to help inform treatment strategies, monitor disease progression or evaluate therapeutic effectiveness.

InVisionFirst®-Lung is a focused and actionable NGS-based liquid biopsy assay covering the guideline-recommended genomic drivers with available targeted therapies. Clinical validation studies have shown a 98% concordance to matched tumor tissue.

Learn about NGS testing at NeoGenomics

References:

  1. NeoGenomics internal data on file.
  2. Solomon JP, et al. Mod Pathol. 2020;33(1):38-46.
  3. Benayed R, et al. Clin Cancer Res. 2019;25(15):4712-4722.
  4. Bruno R, et al. Diagnostics. 2020;10;521.
  5. Aggarwal C, et al. JAMA Oncol. 2019;5(2):173-180.
  6. Meric-Bernstam F, et al. J Clin Oncol. 2015;33(25):2753-2762.
  7. Moore DA, et al. J Clin Pathol. 2018;71:1001-1006.

 

*No patient, healthcare program, or beneficiary shall be billed for these tests. The tests shall not be included in a bundled payment to any healthcare facility including, but not limited to, a hospital. The ordering physician shall not be compensated any fees in connection with this testing, such as for specimen collection, handling, or data reporting. Program is not valid where prohibited by law. NeoGenomics and Lilly reserve the right to rescind, revoke, or amend the program for any reason without notice.

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients